openPR Logo
Press release

Klebsiella Pneumoniae Infections Therapeutics Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight

01-20-2025 10:48 PM CET | Health & Medicine

Press release from: ABNewswire

Klebsiella Pneumoniae Infections Therapeutics Market Size

DelveInsight's comprehensive report titled "Klebsiella Pneumoniae Infections Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Klebsiella Pneumoniae Infections. The report presents historical and projected epidemiological data covering Total Diagnosed Prevalent Cases of Klebsiella Pneumoniae Infections and Treatable Cases of Klebsiella Pneumoniae Infections. In addition to epidemiology, the market report encompasses various aspects related to the patient population.

Unlock key insights into the Klebsiella Pneumoniae Infections Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Klebsiella Pneumoniae Infections Market Size [https://www.delveinsight.com/sample-request/klebsiella-pneumoniae-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Klebsiella Pneumoniae Infections Market Report

* In the United States, Klebsiella pneumoniae is responsible for most human illnesses. Many Klebsiella infections are acquired in the hospital setting or in long-term care facilities. In fact, Klebsiellae account for up to 8% of all hospital-acquired infections.
* K. pneumonia is considered the most common cause of hospital-acquired pneumonia in the US, and the organism accounts for 3% to 8% of all nosocomial bacterial infections.
* The prevalence of Klebsiella pneumonia was reported to be 24% in adults admitted to intensive care units in healthcare settings in France.
* K. pneumoniae accounts for approximately 11.8% of all hospital-acquired pneumonia globally.
* Approximately 8% to 12% of pneumonia cases occur in individuals on ventilators, often attributed to Klebsiella pneumoniae. Contrastingly, only 7% of pneumonia instances arise in patients who are not ventilated.
* The leading Klebsiella Pneumoniae Infections Companies such as Iterum Therapeutics, LimmaTech Biologics/ GSK , and others.
* Promising Klebsiella Pneumoniae Infections Therapies such as ORLYNVAH (sulopenem etzadroxil and probenecid), Kleb4V, Tigecycline, and others.

Stay ahead in the competitive landscape of the Klebsiella Pneumoniae Infections Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Klebsiella Pneumoniae Infections Treatment Market Size [https://www.delveinsight.com/sample-request/klebsiella-pneumoniae-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Klebsiella Pneumoniae Infections Epidemiology Segmentation in the 7MM

* Klebsiella Pneumoniae Infections Type-specific Diagnosed Prevalent Cases
* Total Klebsiella Pneumoniae Infections Diagnosed Prevalent Cases
* Klebsiella Pneumoniae Infections Treatable Cases

Download the report to understand which factors are driving Klebsiella Pneumoniae Infections epidemiology trends @ Klebsiella Pneumoniae Infections Prevalence [https://www.delveinsight.com/sample-request/klebsiella-pneumoniae-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Klebsiella Pneumoniae Infections Treatment Market

The treatment goal remains effective eradication of the infection while minimizing the development of antibiotic resistance, reflecting the ongoing efforts to combat this challenging pathogen. While there is no cure, supportive care, management of complications, and ongoing research aim to enhance the overall well-being of individuals living with Klebsiella Pneumoniae Infections.

Klebsiella Pneumoniae Infections Therapeutics Market

The evolving landscape of antibiotic resistance is poised to undergo significant shifts driven by the emergence of novel therapies. Promising advancements such as novel antibiotics targeting unique bacterial pathways, combination treatments to enhance efficacy, and alternative modalities like phage therapy and monoclonal antibodies offer targeted solutions crucial for combating multidrug-resistant Klebsiella pneumoniae infections and shaping future market dynamics.

Discover the future of Klebsiella Pneumoniae Infections treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Klebsiella Pneumoniae Infections Market Drivers and Barriers [https://www.delveinsight.com/sample-request/klebsiella-pneumoniae-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Klebsiella Pneumoniae Infections Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Klebsiella Pneumoniae Infections Companies- Iterum Therapeutics, LimmaTech Biologics/ GSK, and others.
* Klebsiella Pneumoniae Infections Therapies- ORLYNVAH (sulopenem etzadroxil and probenecid), Kleb4V, Tigecycline, and others.
* Klebsiella Pneumoniae Infections Therapeutic Assessment: Klebsiella Pneumoniae Infections Current Marketed and Klebsiella Pneumoniae Infections Emerging Therapies
* Klebsiella Pneumoniae Infections Market Dynamics: Klebsiella Pneumoniae Infections market drivers and Parkinson's Disease market barriers
* Klebsiella Pneumoniae Infections Unmet Needs, KOL's views, Analyst's views, Klebsiella Pneumoniae Infections Market Access and Reimbursement

Explore the dynamics of the Klebsiella Pneumoniae Infections Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Klebsiella Pneumoniae Infections Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/klebsiella-pneumoniae-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights.

2. Report Introduction.

3. Klebsiella Pneumoniae Infections Epidemiology and Market Overview at a Glance.

4. Executive Summary of Klebsiella Pneumoniae Infections.

5. Disease Background and Overview.

6. Epidemiology and Patient Population.

7. Patient Journey.

8. Klebsiella Pneumoniae Infections: Market Analysis.

9. Key Opinion Leaders' Views.

10. SWOT Analysis.

11. Unmet Needs.

12. Market Access and Reimbursement.

13. Appendix.

14. Report Methodology.

15. DelveInsight Capabilities.

16. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=klebsiella-pneumoniae-infections-therapeutics-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Klebsiella Pneumoniae Infections Therapeutics Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight here

News-ID: 3823702 • Views:

More Releases from ABNewswire

Genloop Meets Prime Minister Narendra Modi to Advance Vision for Ethical, Scalable AI in India
Genloop Meets Prime Minister Narendra Modi to Advance Vision for Ethical, Scalab …
Genloop leaders met with India's Prime Minister to discuss advancing ethical, scalable AI from innovation to real-world deployment. Santa Monica, CA - January 14, 2026 - Genloop [https://genloop.ai/?utm_source=ABNews&utm_medium=email&utm_campaign=1752vc], a portfolio company of 1752vc [http://1752.vc/?utm_source=abnews] (formerly Pegasus Angel Accelerator), announced that its leadership met with the Prime Minister of India, Narendra Modi, at his official residence, 7 Lok Kalyan Marg, for a high-level strategic discussion on the future of artificial intelligence in
Alopecia Areata Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly, Incyte, Throne Biotech, Legacy Healthcare
Alopecia Areata Market to Witness Promising Upswing by 2034, DelveInsight Foreca …
The Key Alopecia Areata Companies in the market include - Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others. The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage
Neko Case Neon Grey Midnight Green 2026: Affordable Tickets + CITY10 Code for Instant Savings
Neko Case Neon Grey Midnight Green 2026: Affordable Tickets + CITY10 Code for In …
Neko Case's Neon Grey Midnight Green Tour rocks North America in 2026, celebrating her acclaimed Sept 2025 album-first new solo work since 2018-with raw, live-recorded tracks, powerful vocals, and hits like "Hold On, Hold On." Catch her with Des Demonas (East/Midwest) or Destroyer (West) from Jan 8 Montreal to March dates in CO, CA & more! Neko Case [https://www.capitalcitytickets.com/Neko-Case-Tickets] is embarking on her electrifying Neon Grey Midnight Green Tour in 2026,
Toogood Gold Expands Footprint, Positioned for High-Impact Growth 2026 Alongside: ADMQ, BMXI, CSDX, SIGL
Toogood Gold Expands Footprint, Positioned for High-Impact Growth 2026 Alongside …
Toogood Gold Corp. (TSXV: TGC | OTCQB: TGGCF) reported final drilling assays from its 100%-owned Toogood Gold Project in Newfoundland, delivering results that significantly expand the scale, continuity, and upside potential of its gold discovery heading into 2026. The Company's 2025 drill program confirmed the Quinlan target as a large, coherent gold system, with gold intersected in all 30 drill holes completed to date. High-grade intervals and visible gold were reported

All 5 Releases


More Releases for Klebsiella

Klebsiella pneumoniae Infections Market is expected to reach USD 7.21 billion by …
The global Klebsiella pneumoniae Infections Market was valued at USD 3.85 billion in 2024 and is expected to reach USD 7.21 billion by 2034, growing at a CAGR of 6.5% during the forecast period (2025-2034). Rising antimicrobial resistance (AMR), increasing hospitalization rates, expanding ICU admissions, and the growing prevalence of community- and hospital-acquired infections are key factors driving market growth. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71746 Klebsiella pneumoniae
Klebsiella Pneumoniae Infections Market is projected to reach USD 5.0 billion by …
Klebsiella pneumoniae is a Gram-negative bacterium responsible for a wide range of healthcare- and community-acquired infections, including pneumonia, bloodstream infections, urinary tract infections (UTIs), and liver abscesses. It is a major concern in intensive care units (ICUs) and among immunocompromised patients. The growing global burden of antimicrobial resistance (AMR) has made Klebsiella pneumoniae one of the most dangerous pathogens, particularly strains resistant to carbapenems, cephalosporins, and aminoglycosides. The World Health Organization
Klebsiella Infections Therapeutics- Pipeline Analysis 2018, Clinical Trials & Re …
Klebsiella infections include different types of infections like bloodstream infections; pneumonia; wound or surgical site infections; and meningitis, caused by the Klebsiella bacteria. The symptoms associated with these infections are high fevers, chills, cough, and shortness of breath. Download the sample report @ https://www.pharmaproff.com/request-sample/1065 Hospitalized patients undergoing treatment for other conditions may be susceptible to these infections. In healthcare settings, patients who require long courses of antibiotics, or are treated with
Klebsiella Pneumoniae Infections Market Symptoms, Consulting Services, Epidemiol …
Klebsiella Pneumoniae Infections Market Epidemiology outlays comprehensive Insight of the disease, historical & forecasted epidemiology as well as the market trends of Klebsiella Pneumoniae Infections Industry. The Report provides a detailed picture of the current treatment practices, emerging drugs, a market share of the individual therapies, current and forecasted market size of Klebsiella Pneumoniae Infections. The Klebsiella Pneumoniae Infections Market Report also covers current treatment practice/algorithm, market drivers, market barriers and
Klebsiella pneumoniae Infections Market : Potential and Niche Segments, Geograph …
ReportBazzar has released its latest research-based report entitled ‘Klebsiella pneumoniae Infections’ market. This report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Klebsiella pneumoniae Infections market. The report also provides a detailed analysis of key trends and latest technologies, playing a prominent role in the Klebsiella pneumoniae Infections market growth. It takes into account aspects such as drivers,
Klebsiella pneumoniae Infections (Infectious Disease) Pipeline Forecast Report, …
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2017, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape. Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic